HyperRho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) Indications/Uses

Pregnancy and Other Obstetric Conditions: Prevention of Rh hemolytic disease of the newborn by its administration to the Rho(D)-negative mother within 72 hrs after birth of a Rho(D)-positive infant, providing the following criteria are met: The mother must be Rho(D)-negative and must not already be sensitized to the Rho(D) factor; her child must be Rho(D)-positive and should have a negative direct antiglobulin test (see Precautions).
If Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose is administered antepartum, it is essential that the mother receive another dose of Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose after delivery of a Rho(D)-positive infant.
If the father can be determined to be Rho(D)-negative, Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose need not be given.
Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose should be administered within 72 hrs to all non-immunized Rho(D)-negative women who have undergone spontaneous or induced abortion, following ruptured tubal pregnancy, amniocentesis or abdominal trauma unless the blood group of the fetus or the father is known to be Rho(D)-negative. If the fetal blood group cannot be determined, one must assume that it is Rho(D)-positive and Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose should be administered to the mother.
Transfusion: Bayrho-D (Rho(D) Immune Globulin-Human) (SD Viral Inactivated) full dose may be used to prevent isoimmunization in Rho(D)-negative individuals who have been transfused with Rho(D)-positive red blood cells or blood components containing red blood cells.